Abstract:OBJECTIVE:To evaluate the diagnostic value of serum galactomannan antigen (GM) and (1→3)-β-D-glucan antigen (BG) assay in invasive fungal infections (IFI) in the patients with hematologic malignancies and the role in monitoring therapeutic response.METHODS:Fifty one patients with hematological malignancies met the criteria for inclusion: (1) body temperature above 38°C for 48 hours, (2) failure to respond to broad-spectrum antibiotic treatment, or (3) temperature rose again after the responded drop. Blood samples were collected twice at the first week, then once a week in at least four weeks. The double antibody sandwich enzyme-linked immunosorbent assay (ELISA) and colorimetric assay were used for detecting GM and BG. The positive GM test is defined as two consecutive tests at different time GM value > 0.5 or > 0.8 and the positive G test is defined as BG value > 80 pg/ml. The patients were assigned into four groups as proven, probable, possible, and non-fungal infection respectively, and 21 normal volunteers were as controls.RESULTS:Two hundred and forty serum samples were collected from 51 patients including 2 of proven IFI, 26 probable IFI, 17 possible IFI and 6 non-fungal infection. The true-positive group including the proven and probable groups, and true negative group was the non-fungal infection group. GM tests were positive in 21 of 28 cases in true positive group, and only one of 6 cases in non-fungal infection. The sensitivity, specificity, positive predictive value and negative predictive value were 75%, 83.3%, 95.5% and 41.7%, respectively. G tests were positive in all 28 cases of the true positive group, and 4 in 6 non-fungal infection cases. The sensitivity, specificity, positive predictive value and negative predictive value were 100%, 33.3%, 87.5% and 100%, respectively. G test is more sensitive than GM test (P = 0.015), but there was no significant difference in specificity of the two tests (P = 0.242). In 19 of 21 patients with GM test positive, anti-fungal treatment was effective, and GM value gradually decreased to negative, two invalid patients were persistent with GM test positive. After two weeks treatment, the average GM value was significantly lower in the effective group than in the ineffective group (P < 0.05). BG values in the responded patients showed a gradual decline similar to that of GM values, but not to negative. The changes of BG value in ineffective group varied with a trend upward. The changes in BG value had no relation with treatment effectiveness.CONCLUSIONS:Serum GM and BG antigens detection provides strong evidence for early diagnosis of IFI. Combination of GM and G tests can improve the diagnostic specificity and reduce the false positive GM test seems superior to G test for monitoring GM and BG values during treatment.

The detection of (1,3)-beta-D-glucosan in hematological patients with invasive fungal disease

The Diagnostic Significance of G/GM Assay for Invasive Fungal Infections in Patients with Hematological Malignancies

[Early Antigen Diagnosis of Invasive Fungal Infection in Patients with Hematological Malignancies and Patients Receiving Hematopoietic Stem Cell Transplantation].

Detection Of(1,3)-Β-d-glucan and Galactomannan for Diagnosis of Invasive Fungal Disease

The Diagnostic Efficiency Evaluation of Combination Tuberculosis Interferon-Gamma Release Assay with Human Leukocyte Antigen-G for Tuberculosis

Evaluation of Domestic Plasma (1 -3)-β-d-glucan Detection Reagent in Diagnosis of Invasive Fungal Disease

The Clinical Value of Measuring the (1-3)-β-D-Glucan and Galactomannan for Diagnosis of Invasive Fungal Disease

[The Significance of Serum GM and BG Antigens Assay for Invasive Fungal Infections in Hematological Malignancies Patients].

Diagnostic performance of the (1-3)-β-d-glucan assay in patients with different risks for invasive fungal diseases

Clinical Evaluation of (1, 3)-β-D-glucan in the Diagnosis of Invasive Fungal Infection

Value of Serum Galactomannan Enzyme Immunoassay Combine with 1, 3 Beta-Glucan Assay for Diagnosis of Invasive Fungal Infection in Hematological Disorders

[Investigation of the Cutoff Value of a Serum 1,3-Beta-d-glucan Assay for Early Diagnosis of Invasive Fungal Infection in Chinese Hematopoietic Stem Cell Transplant Recipients].

Serum Galactomannan Antigen Assay and 1,3 Beta-D-glucan Assay in the Diagnosis of Invasive Fungal Infection after Hematopoietic Stem Cell Transplantation

The diagnostic value of detecting plasma 1,3-β-D-glucan for invasive fungal infections

Clinical evaluation of two different (1,3)-ß-d-glucan assays for diagnosis of invasive fungal diseases: A retrospective cohort study

1701. Differences in Diagnostic Performance of Β-D-glucan Testing in Patients with Varying Degrees of Susceptibility to Invasive Fungal Infections

��清半乳甘露聚糖和血浆（1，3）β—d-葡聚糖检测诊断侵袭性真菌感染

Detection Of Galactomannan And (1-3)-Beta-D-Glucan For Early Diagnosis Of Invasive Aspergillosis In Hematological Cancer Patients

Diagnostic Value of (1,3)-Β-d-glucan Assay and Galactomannan Test for Invasive Fungal Infection in Patients of Acute Radiation Sickness

[Value of Plasma Beta-Glucan in Early Diagnosis of Invasive Fungal Infection in Children].

Assay of Plasma (1→3)-Β-d-glucan in Patients Suspected with Deep Fungal Infection